Lyell Immunopharma Inc.

12/09/2024 | Press release | Distributed by Public on 12/09/2024 20:40

Lyell Presents Positive Initial Clinical Data from the Phase 1 2 Clinical Trial of IMPT 314 for the Treatment of B cell Lymphoma at the 2024 ASH Annual Meeting

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.